Dr. Kazumi Shiosaki began working with MPM in 2001 as an Entrepreneur-in-Residence while also holding the position of Senior Vice President of Scientific Development at Millennium Pharmaceuticals. Since joining MPM full time in 2003, she has helped to found and served as the start-up CEO of several MPM portfolio companies including Primera Diagnostics and most recently Epizyme. In addition, Dr. Shiosaki has played important advisory roles for Hypnion (where she was involved in the identification of the lead compound that lead to the sale of the company to Lilly in 2007), Oxagen and Aryx. Dr. Shiosaki brings to MPM nearly 17 years of strategic and operational experience in the pharmaceutical-biotechnology industry with a career that began at Abbott Laboratories where she worked on drug discovery programs in a number of therapeutic areas including Neuroscience, Cardiovascular, and Infectious Disease. At Millennium Pharmaceuticals, where she was Senior Vice President of Drug Discovery, she helped lead the efforts to transition Millennium from a genomics into a drug discovery organization and was part of the team that secured as well as implemented the large, precedent-setting pharma partnerships. Dr. Shiosaki received her Ph.D. in Synthetic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from Whitman College.
Sai Advantium Pharma Limited
Past Portfolio Assignments